Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study

Laurie H. Sehn, Andre Goy, Fritz C. Offner, Giovanni Martinelli, M. Dolores Caballero, Ole Gadeberg, Tara Baetz, Andrew D. Zelenetz, Gianluca Gaidano, Luis E. Fayad, Rena Buckstein, Jonathan W. Friedberg, Michael Crump, Branimir Jaksic, Pier Luigi Zinzani, Swaminathan Padmanabhan Iyer, Deniz Sahin, Akiko Chai, Günter Fingerle-Rowson, Oliver W. Press

Research output: Contribution to journal › Article › peer-review

138 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study'. Together they form a unique fingerprint.

Medicine & Life Sciences